Search research articles
Contact Us
Filters
Showing results (461-470 of 509) with videos related to
Page
of 51
Sort By:
The Lancet. Oncology
|
November 16, 2024
Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial
Jean-Marc Classe, Pierre Meeus, Delphine Hudry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Rachel N Grisham, Ignace Vergote, Susana Banerjee, et al.
Cancer Research Communications
|
June 28, 2023
Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Anne-Sophie Sertier, Anthony Ferrari, Roxane M Pommier, et al.
Translational Oncology
|
July 1, 2026
Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial
Pauline Corbaux, Olivier Colomban, Gaelle Lescuyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Circulating tumor DNA for prognostication and monitoring in patients with metastatic endometrial carcinoma treated with olaparib: validation in the GINECO-UTOLA trial
Guillaume Beinse, Valerie Taly, Alexandra Leary, et al.
Cell Death and Differentiation
|
August 26, 2023
Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor
Benjamin Ducarouge, Anna-Rita Redavid, Camille Victoor, et al.
Gynecologic Oncology
|
January 27, 2023
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial
Gwénaël Ferron, Gaëtan De Rauglaudre, Stéphanie Becourt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
Bradley J Monk, Rachel N Grisham, Susana Banerjee, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
Domenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
Nature
|
August 2, 2023
Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer
Philippe A Cassier, Raul Navaridas, Melanie Bellina, et al.
Page
of 51
Search research articles
Search
Showing results (461-470 of 509) with videos related to
Sort By:
Page
of 51
The Lancet. Oncology
|
November 16, 2024
Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial
Jean-Marc Classe, Pierre Meeus, Delphine Hudry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Rachel N Grisham, Ignace Vergote, Susana Banerjee, et al.
Cancer Research Communications
|
June 28, 2023
Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Anne-Sophie Sertier, Anthony Ferrari, Roxane M Pommier, et al.
Translational Oncology
|
July 1, 2026
Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial
Pauline Corbaux, Olivier Colomban, Gaelle Lescuyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Circulating tumor DNA for prognostication and monitoring in patients with metastatic endometrial carcinoma treated with olaparib: validation in the GINECO-UTOLA trial
Guillaume Beinse, Valerie Taly, Alexandra Leary, et al.
Cell Death and Differentiation
|
August 26, 2023
Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor
Benjamin Ducarouge, Anna-Rita Redavid, Camille Victoor, et al.
Gynecologic Oncology
|
January 27, 2023
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial
Gwénaël Ferron, Gaëtan De Rauglaudre, Stéphanie Becourt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
Bradley J Monk, Rachel N Grisham, Susana Banerjee, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
Domenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
Nature
|
August 2, 2023
Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer
Philippe A Cassier, Raul Navaridas, Melanie Bellina, et al.
Page
of 51